Relevant bibliographies by topics / Rheumatoid arthritis Prognosis / Journal articles

Journal articles on the topic 'Rheumatoid arthritis Prognosis'

To see the other types of publications on this topic, follow the link: Rheumatoid arthritis Prognosis.
Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Rheumatoid arthritis Prognosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Weisman, Michael H. "Prognosis in rheumatoid arthritis." Current Opinion in Rheumatology 2, no. 3 (June 1990): 458–62. http://dx.doi.org/10.1097/00002281-199002030-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ciofoaia, Elena I., Anjani Pillarisetty, and Florina Constantinescu. "Health disparities in rheumatoid arthritis." Therapeutic Advances in Musculoskeletal Disease 14 (January 2022): 1759720X2211371. http://dx.doi.org/10.1177/1759720x221137127.

Full text
Abstract:
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation that involves symmetric polyarthritis of small and large joints. Autoimmune rheumatic diseases represent a significant socioeconomic burden as they are among the leading causes of death and morbidity due to increased risk of cardiovascular disease. Health disparities in patients with rheumatoid arthritis affect outcomes, prognosis, and management of the disease.
APA, Harvard, Vancouver, ISO, and other styles
3

Dariushnejad, Hassan, Leila Chodari, Mehrnoosh Sedighi, Soheila Akbari, and Vajihe Ghorbanzadeh. "Rheumatoid arthritis: current therapeutics compendium." Endocrine Regulations 56, no. 2 (April 1, 2022): 148–62. http://dx.doi.org/10.2478/enr-2022-0016.

Full text
Abstract:
Abstract Rheumatoid arthritis is a common chronic inflammatory disease with substantial economic, social, and personal costs. Its pathogenesis is multifactorial and complex. The ultimate goal of rheumatoid arthritis treatment is stopping or slowing down the disease progression. In the past two decades, invention of new medicines, especially biologic agents, revolutionized the management of this disease. These agents have been associated with an improved prognosis and clinical remission, especially in patients who did not respond to traditional disease-modifying anti-rheumatic drugs (DMARDs). Improvement in the understanding of the rheumatoid arthritis pathogenesis leads to the development of novel biologic therapeutic approaches. In the present paper, we summarized the current therapeutics, especially biologic agents, available for the treatment of rheumatoid arthritis.
APA, Harvard, Vancouver, ISO, and other styles
4

Kahan, A., and C.-J. Menkès. "The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis–the French Experience." Lupus 5, no. 1_suppl (June 1996): 45–49. http://dx.doi.org/10.1177/0961203396005001111.

Full text
Abstract:
A significant proportion of patients with rheumatoid arthritis have an aggressive, severe disease that may contribute to excess mortality. It has been suggested that early, aggressive therapy might improve the prognosis of these patients with active, severe rheumatoid arthritis. Combinations of disease modifying anti-rheumatic drugs including antimalarials are increasingly used in patients with active disease. While several open trials showed encouraging results, some controlled studies gave less support for the use of combination therapy. Ongoing controlled trials of double or triple combination therapy, such as hydroxychloroquine, methotrexate and sulphasalazine, should help define its place in treating patients with rheumatoid arthritis.
APA, Harvard, Vancouver, ISO, and other styles
5

Anghel, Daniela, Oana-Georgiana Petrache, Maria Laura Groșeanu, Maria Magdalena Negru, Cristina Florentina Pleșa, and Florentina Ioniţă Radu. "The Implication of Videocapillaroscopy in Rheumatoid Arthritis and Psoriatic Arthritis." Internal Medicine 19, no. 2 (February 1, 2022): 55–61. http://dx.doi.org/10.2478/inmed-2022-0207.

Full text
Abstract:
Abstract Videocapillaroscopy is an easy, noninvasive examination method that detects morphological microvascular abnormalities, such as nailfold capillaries. This method has a low cost, has high sensitivity and specificity, has reproductibility and the results can be easily interpreted. Besides its importance in the evaluation of Raynaud’s phenomenon and systemic sclerosis, nailfold capillaroscopy may play an important role in the diagnosis, evaluation and prognosis of other rheumatic diseases, such as rheumatoid arthritis and psoriatic arthritis. Because there are not enough data, currently, capillaroscopy is not routinely used in these patients. The aim of this review is to present the implications of the videocapillaroscopy in rheumatic diseases, other than systemic sclerosis, in order to promote this method as a routine investigation in rheumatic patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Druce, Katie L., and Neil Basu. "Predictors of fatigue in rheumatoid arthritis." Rheumatology 58, Supplement_5 (November 1, 2019): v29—v34. http://dx.doi.org/10.1093/rheumatology/kez346.

Full text
Abstract:
Abstract People with RA commonly experience fatigue. Fatigue is a key contributor to increased clinical care costs, primary care consultations and employment loss. Despite this, our understanding of the prognostic of factors of poor fatigue outcomes is lacking and fatigue is poorly managed. Examining longitudinal predictors of fatigue can identify both individuals ‘at risk’ of poor prognosis, and candidate mechanisms that are worthy of greater inspection. This review discusses the factors most commonly investigated as being implicated in the prognosis of RA fatigue. The available data appears to implicate generic factors such as pain, mental health, disability and sleep as consistent predictors of fatigue outcome, while the role of disease activity and inflammation seems less clear. However, the existing data are not without methodological limitations and there have been no specific studies primarily designed to investigate the inflammatory biomarkers of fatigue. Future studies are required to more comprehensively and robustly determine the mechanisms of fatigue.
APA, Harvard, Vancouver, ISO, and other styles
7

Lu, Haifeng, Yujun Yao, Jiezuan Yang, Hua Zhang, and Lanjuan Li. "Microbiome–miRNA interactions in the progress from undifferentiated arthritis to rheumatoid arthritis: evidence, hypotheses, and opportunities." Rheumatology International 41, no. 9 (April 15, 2021): 1567–75. http://dx.doi.org/10.1007/s00296-021-04798-3.

Full text
Abstract:
AbstractThe human microbiome has attracted attention for its potential utility in precision medicine. Increasingly, more researchers are recognizing changes in intestinal microbiome can upset the balance between pro- and anti-inflammatory factors of host immune system, potentially contributing to arthritis immunopathogenesis. Patients who develop rheumatoid arthritis from undifferentiated arthritis can face multiple irreversible joint lesions and even deformities. Strategies for identifying undifferentiated arthritis patients who have a tendency to develop rheumatoid arthritis and interventions to prevent rheumatoid arthritis development are urgently needed. Intestinal microbiome dysbiosis and shifts in the miRNA profile affect undifferentiated arthritis progression, and may play an important role in rheumatoid arthritis pathophysiologic process via stimulating inflammatory cytokines and disturbing host and microbial metabolic functions. However, a causal relationship between microbiome–miRNA interactions and rheumatoid arthritis development from undifferentiated arthritis has not been uncovered yet. Changes in the intestinal microbiome and miRNA profiles of undifferentiated arthritis patients with different disease outcomes should be studied together to uncover the role of the intestinal microbiome in rheumatoid arthritis development and to identify potential prognostic indicators of rheumatoid arthritis in undifferentiated arthritis patients. Herein, we discuss the possibility of microbiome–miRNA interactions contributing to rheumatoid arthritis development and describe the gaps in knowledge regarding their influence on undifferentiated arthritis prognosis that should be addressed by future studies.
APA, Harvard, Vancouver, ISO, and other styles
8

Shlopak, Lev. "Diagnosis of rheumatoid arthritis." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 3 (March 1, 2020): 29–36. http://dx.doi.org/10.33920/med-10-2003-03.

Full text
Abstract:
Rheumatoid arthritis is a chronic systemic autoimmune disease of the connective tissue, accompanied by a primary lesion of peripheral joints with the development of erosive-destructive changes and ankylosis. It is one of the most common chronic inflammatory diseases in humans. Early diagnosis of this pathology contributes to the timely start of therapy, which allows to reduce the level of disability and improve the prognosis for this group of patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Бестаев, D. Bestaev, Божьева, and L. Bozheva. "Clinical, laboratory and instrumental characteristics in patients with rheumatoid arthritis with "ground glass opacity" computed tomographic symptom of interstitial lung disease." Journal of New Medical Technologies. eJournal 9, no. 1 (April 17, 2015): 0. http://dx.doi.org/10.12737/10474.

Full text
Abstract:
Rheumatoid arthritis is an inflammatory rheumatic disease with unknown etiology characterized by symmetric, chronic and erosive arthritis (synovitis) of the peripheral joints and systemic inflammatory involvement of the viscera. Lung pathology, including interstitial lung disease, is one of the common extra-articular manifestations at the гheumatoid arthritis. The leading diagnosis method of interstitial lung disease is a computed tomography high resolution, which allows to identifying interstitial lung changes in 70% of the cases. The study of prognosis in patients with rheumatoid arthritis interstitial lung disease has been the subject of several studies in the past decade. In most studies it was stated that the average life expectancy from diagnosis is around 3 years. This work is devoted to study of interstitial lung disease as one of the most frequent extra-articular ma-nifestations of rheumatoid arthritis. The authors defined the significance of computed tomography high resolu-tion for the diagnosis of pulmonary interstitial lung changes at rheumatoid arthritis. They give comparative clini-cal and immunological, instrumental characteristics of rheumatoid arthritis patients with interstitial lung disease and without it. The role of smoking and positivity of anti-cyclic citrullinated peptide (anti-CCP) according to antibodies are determined as risk factors of interstitial lung disease development in patients with rheumatoid arthritis. The interrelation of the X-ray tomography symptom of interstitial lung disease "ground glass opacity" with the activity and duration of rheumatoid arthritis is revealed. "Ground glass opacity" symptom is associated with high index of DAS28 in patients with rheumatoid arthritis with interstitial lung disease.
APA, Harvard, Vancouver, ISO, and other styles
10

Dakin, Stephanie G. "Synovial signatures signpost arthritis." Science Translational Medicine 11, no. 488 (April 17, 2019): eaax1725. http://dx.doi.org/10.1126/scitranslmed.aax1725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Rasker, J. J., and J. A. Cosh. "Course and Prognosis of Early Rheumatoid Arthritis." Scandinavian Journal of Rheumatology 18, sup79 (January 1989): 45–56. http://dx.doi.org/10.3109/03009748909092612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Paroli, M. P., S. Speranza, M. Marino, M. P. Pirraglia, and P. Pivetti-Pezzi. "Prognosis of Juvenile Rheumatoid Arthritis-Associated Uveitis." European Journal of Ophthalmology 13, no. 7 (August 2003): 616–21. http://dx.doi.org/10.1177/112067210301300704.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Bendtsen, Preben, and Jan Olof Hörnquist. "Disease course and prognosis in rheumatoid arthritis." Scandinavian Journal of Social Medicine 24, no. 3 (September 1996): 193–98. http://dx.doi.org/10.1177/140349489602400311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Skielta, Mattias, Lars Söderström, Solbritt Rantapää-Dahlqvist, Solveig W. Jonsson, and Thomas Mooe. "Trends in mortality, co-morbidity and treatment after acute myocardial infarction in patients with rheumatoid arthritis 1998–2013." European Heart Journal: Acute Cardiovascular Care 9, no. 8 (January 28, 2020): 931–38. http://dx.doi.org/10.1177/2048872619896069.

Full text
Abstract:
Aims: Rheumatoid arthritis may influence the outcome after an acute myocardial infarction. We aimed to compare trends in one-year mortality, co-morbidities and treatments after a first acute myocardial infarction in patients with rheumatoid arthritis versus non-rheumatoid arthritis patients during 1998–2013. Furthermore, we wanted to identify characteristics associated with mortality. Methods and results: Data for 245,377 patients with a first acute myocardial infarction were drawn from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions for 1998–2013. In total, 4268 patients were diagnosed with rheumatoid arthritis. Kaplan-Meier analysis was used to study mortality trends over time and multivariable Cox regression analysis was used to identify variables associated with mortality. The one-year mortality in rheumatoid arthritis patients was initially lower compared to non-rheumatoid arthritis patients (14.7% versus 19.7%) but thereafter increased above that in non-rheumatoid arthritis patients (17.1% versus 13.5%). In rheumatoid arthritis patients the mean age at admission and the prevalence of atrial fibrillation increased over time. Congestive heart failure decreased more in non-rheumatoid arthritis than in rheumatoid arthritis patients. Congestive heart failure, atrial fibrillation, kidney failure, rheumatoid arthritis, prior diabetes mellitus and hypertension were associated with significantly higher one-year mortality during the study period 1998–2013. Conclusions: The decrease in one-year mortality after acute myocardial infarction in non-rheumatoid arthritis patients was not applicable to rheumatoid arthritis patients. This could partly be explained by an increased age at acute myocardial infarction onset and unfavourable trends with increased atrial fibrillation and congestive heart failure in rheumatoid arthritis. Rheumatoid arthritis per se was associated with a significantly worse prognosis.
APA, Harvard, Vancouver, ISO, and other styles
15

Morgan, James G., and Wen-Shiung Chow. "Clinical features, diagnosis, and prognosis in rheumatoid arthritis." Current Opinion in Rheumatology 5, no. 2 (March 1993): 184–90. http://dx.doi.org/10.1097/00002281-199305020-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

McGonagle, Dennis, Wayne Gibbon, Philip O'Connor, Michael Green, Colin Pease, John Ridgway, and Paul Emery. "An anatomical explanation for good-prognosis rheumatoid arthritis." Lancet 353, no. 9147 (January 1999): 123–24. http://dx.doi.org/10.1016/s0140-6736(05)76160-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

MOREL, J., and B. COMBE. "How to predict prognosis in early rheumatoid arthritis." Best Practice & Research Clinical Rheumatology 19, no. 1 (February 2005): 137–46. http://dx.doi.org/10.1016/j.berh.2004.08.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Mendoza-Vázquez, Guadalupe, Francisco Espinoza-Gómez, Alberto Daniel Rocha-Muñoz, Jorge I. Gamez-Nava, Laura Gonzalez-Lopez, Mario Salazar-Paramo, Carlos Riebeling-Navarro, Javier Alejandro Aceves-Aceves, Sandra Guzmán-Silahua, and Arnulfo Hernán Nava-Zavala. "Correlation between percentage of fat mass and level of disease activity in rheumatoid arthritis." SAGE Open Medicine 10 (January 2022): 205031212210858. http://dx.doi.org/10.1177/20503121221085821.

Full text
Abstract:
Introduction: Controversies exist regarding the relationship between body fat and disease activity in patients with rheumatoid arthritis. The evaluation of the disease is critical for establishing treatment and prognosis. Fat mass could be a predictive factor for poor prognosis in rheumatoid arthritis because of its association with low- and high-grade inflammation. Objective: To evaluate the correlation between fat mass values and disease activity in patients with rheumatoid arthritis. Materials and methods: This was a cross-sectional study. Eighty female patients diagnosed with rheumatoid arthritis (American College of Rheumatology of 1987) were evaluated. For each one, the evaluation determined fat mass using bioelectrical impedance analysis and disease activity using the Disease Activity Score on 28 joints (DAS28). Results: The mean age was 59.11 ± 9.92 years, with an average disease duration of 14.13 ± 10.13 years; 85% of patients showed a high body fat percentage. Pearson’s correlation between DAS28 values and fat mass was r = 0.035 ( p = 0.76). Conclusion: The levels of DAS28 showed no correlation with fat mass percentage. Further studies are required to clarify the factors that can modify these levels.
APA, Harvard, Vancouver, ISO, and other styles
19

Omelchenko, V. O., M. A. Korolev, T. I. Pospelova, and V. I. Konenkov. "Cardiovascular risk in rheumatoid arthritis." Clinical Medicine (Russian Journal) 96, no. 6 (November 11, 2018): 491–97. http://dx.doi.org/10.18821/0023-2149-2018-96-6-491-497.

Full text
Abstract:
The problem of high mortality in patients with rheumatoid arthritis, one of the most common autoimmune diseases, is still unsolved. Many studies have shown a significant impact on cardiovascular risk of both traditional and non-traditional risk factors (genetic, RA-associated etc). To improve the individual prognosis, team actions by physicians of different specialties are necessary on the basis of good awareness and patients ’ compliance. The aim of the review was to characterize the main factors involved in the formation of cardiovascular risk and give a notion about the features of its assessing in patients with rheumatoid arthritis. Literature search was carried out using Scopus, Web of Science, RSCI by keywords.
APA, Harvard, Vancouver, ISO, and other styles
20

Tulichev, A. A., N. Yu Borovkova, N. N. Borovkov, A. A. Spassky, I. V. Polyakova, I. Yu Maksimova, and S. Yu Zubova. "Endothelial function and its role in the formation of cardiovascular pathology in patients with rheumatoid arthritis." Kazan medical journal 100, no. 3 (June 13, 2019): 451–56. http://dx.doi.org/10.17816/kmj2019-451.

Full text
Abstract:
Currently rheumatoid arthritis is considered as an immune inflammatory disease of unknown origin characterized by chronic erosive arthritis and systemic damage of internal organs, leading to early disability and reduced life expectancy. Cardiovascular diseases are most often mentioned as factors of poor prognosis in rheumatoid arthritis. Pathology of the cardiovascular system in rheumatoid arthritis is usually associated with the macro- and microvascular changes and rheumatoid lesions of the heart. The leading factor in the damage of the vascular wall in rheumatoid arthritis is systemic inflammation affecting its viscosity and elastic properties, increased rigidity, impaired endothelial function. Endothelial dysfunction is currently regarded to as an initial stage of morphogenesis of various vascular disorders. It is considered as a subclinical marker of cardiovascular diseases and the earliest predictor of cardiovascular complications. From this point of view study of endothelial dysfunction in patients with rheumatoid arthritis aimed at determining cardiovascular risk is a perspective direction. Only single and fragmentary information about certain endothelial functions in patients with rheumatoid arthritis and substances released in this. There is no clear analysis of relationship between them and dependence on the process activity. Not clear is their role in the pathology of the vascular wall in rheumatoid arthritis. This literature review discusses the problem of endothelial dysfunction in rheumatoid arthritis patients as well as its role in the development of cardiovascular diseases in these patients. The development mechanisms and the role of immune inflammation in its formation are considered. Also the association was found between chronic inflammatory activity indicators in rheumatoid arthritis and various biological markers and development of endothelial dysfunction. The effects of antirheumatic treatment on endothelial dysfunction in these patients were analyzed.
APA, Harvard, Vancouver, ISO, and other styles
21

Karstila, K., M. Korpela, S. Sihvonen, H. Helin, and J. Mustonen. "Prognosis of mesangial glomerulonephritis in patients with rheumatoid arthritis." Clinical Nephrology 68, no. 11 (November 1, 2007): 335–36. http://dx.doi.org/10.5414/cnp68335.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Mitchell, Donald M., Patricia W. Spitz, Donald Y. Young, Daniel A. Bloch, Dennis J. McShane, and James F. Fries. "Survival, prognosis, and causes of death in rheumatoid arthritis." Arthritis & Rheumatism 29, no. 6 (June 1986): 706–14. http://dx.doi.org/10.1002/art.1780290602.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Kobak, Senol, and Cemal Bes. "An autumn tale: geriatric rheumatoid arthritis." Therapeutic Advances in Musculoskeletal Disease 10, no. 1 (November 7, 2017): 3–11. http://dx.doi.org/10.1177/1759720x17740075.

Full text
Abstract:
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by erosive arthritis and systemic organ involvement. The disease may affect all ages and both sexes; usually it is seen in young women aged 25–45. Recent studies have shown that RA is among the most common inflammatory disease in older age groups. While elderly-onset rheumatoid arthritis (EORA) is still discussed in the literature, it is generally accepted as a disease beginning after 65 years of age. Compared with young-onset rheumatoid arthritis (YORA), it was found that EORA had different characteristics. EORA is characterized by more equal gender distribution, higher frequency of acute onset with constitutional symptoms, more frequent involvement of large joints, and lower frequency of rheumatoid factor (RF) positivity. Earlier diagnosis, less erosive disease and less disease-modifying antirheumatic drug usage were reported as distinguishing EORA from YORA patients. These various clinical presentations may cause difficulties in diagnosis and differential diagnosis of EORA. However, different clinical and treatment approaches may be needed in these patients. In this article, the clinical and laboratory characteristics, prognosis and treatment principles of EORA will be discussed in light of recent literature data.
APA, Harvard, Vancouver, ISO, and other styles
24

Kmiołek, Tomasz, and Agnieszka Paradowska-Gorycka. "miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis." Cells 11, no. 3 (January 28, 2022): 452. http://dx.doi.org/10.3390/cells11030452.

Full text
Abstract:
Within the past years, more and more attention has been devoted to the epigenetic dysregulation that provides an additional window for understanding the possible mechanisms involved in the pathogenesis of autoimmune rheumatic diseases. Rheumatoid arthritis (RA) is a heterogeneous disease where a specific immunologic and genetic/epigenetic background is responsible for disease manifestations and course. In this field, microRNAs (miRNA; miR) are being identified as key regulators of immune cell development and function. The identification of disease-associated miRNAs will introduce us to the post-genomic era, providing the real probability of manipulating the genetic impact of autoimmune diseases. Thereby, different miRNAs may be good candidates for biomarkers in disease diagnosis, prognosis, treatment and other clinical applications. Here, we outline not only the role of miRNAs in immune and inflammatory responses in RA, but also present miRNAs as diagnostic/prognostic biomarkers. Research into miRNAs is still in its infancy; however, investigation into these novel biomarkers could progress the use of personalized medicine in RA treatment. Finally, we discussed the possibility of miRNA-based therapy in RA patients, which holds promise, given major advances in the therapy of patients with inflammatory arthritis.
APA, Harvard, Vancouver, ISO, and other styles
25

Andrade, X. A., H. E. Fuentes, D. M. Oramas, H. Mann, and P. Kovarik. "Iatrogenic T-Cell Lymphoma with Associated Hemophagocytic Lymphohistiocyotsis in a Patient with Long-Standing Rheumatoid Arthritis." Case Reports in Hematology 2018 (2018): 1–4. http://dx.doi.org/10.1155/2018/8097965.

Full text
Abstract:
Patients with rheumatoid arthritis are at increased risk of hematological malignancies, especially when exposed to immunosuppressive therapy. The mechanisms of lymphomagenesis remain poorly understood but factors implicated include high disease activity, exposure to antitumoral necrosis factor medications, and Epstein–Barr virus infection. Lymphoid malignancies of T-cell origin are uncommon in patients with rheumatoid arthirits. Clinical presentation with associated hemophagocytic lymphohistiocyotsis is rare and confers a poor prognosis. This case report illustrates a case of a patient with long-standing rheumatoid arthritis and an iatrogenic peripheral T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis who achieved a complete response after intensive chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
26

Vlasov, Timur D., Daniel A. Shimanski, Irina I. Nesterovich, and Vasilii I. Trophimov. "The experience of using dark-field microscopy to assess damage to the endothelial glycocalyx in rheumatoid arthritis." HERALD of North-Western State Medical University named after I.I. Mechnikov 12, no. 4 (March 18, 2021): 73–80. http://dx.doi.org/10.17816/mechnikov43846.

Full text
Abstract:
Rheumatoid arthritis is the most common inflammatory joint disease and one of the most common chronic inflammatory diseases. The leading role in the pathogenesis of rheumatoid arthritis is the damage to the endothelial glycocalyx a thin dynamic layer of macromolecules located on the surface of the endothelium and consisting of proteoglycans, glycoproteins and glycosaminoglycans, which contributes to the maintenance of rheumatoid arthritis activity. Therefore, early detection of violations of the vasculr endothelium condition, especially the endothelial glycocalyx, will identify a group of patients with a poor prognosis. In this context, the method of dark-field microscopy may be promising. It allows non-invasive and in vivo assessment of the thickness of the sublingual endothelial glycocalyx, which will make it possible to search for new unconventional risk factors for the unfavorable course of rheumatoid arthritis and cardiovascular risk in these patients, as well as personalize treatment by developing a complex of preventive and therapeutic measures aimed at restoring endothelial function, reducing the risk of cardiovascular complications, disability and mortality from rheumatoid arthritis. The unique capabilities of this research method are demonstrated by the example of the clinical case.
APA, Harvard, Vancouver, ISO, and other styles
27

Codreanu, Cătălin, Corina Mogoșan, Claudiu Costinel Popescu, Simona Rednic, Horațiu Popovici, Magda Pârvu, Daniela Opriș, and Ruxandra Ionescu. "Pre-treatment antinuclear antibody positivity, therapeutic efficacy and persistence of biologics in rheumatoid arthritis." Revista Romana de Medicina de Laborator 24, no. 2 (June 1, 2016): 212–22. http://dx.doi.org/10.1515/rrlm-2016-0018.

Full text
Abstract:
Abstract Introduction: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are poor prognostic factors in rheumatoid arthritis (RA). The therapeutic implication of antinuclear antibody (ANA) positivity in RA is still debated. The study aims to evaluate ANA positivity as a prognostic factor for the therapeutic response to biologics in RA. Methods: observational study; data were gathered from the Romanian Registry of Rheumatic Diseases which comprises all biological-treated RA patients in Romania. We included only RA patients who were tested for ANA before initiating biologics. Results: A number of 740 RA patients were included (72.4% treated with TNF-α blockers, 27.6% with rituximab). Compared to ANA-negative patients, ANA-positive patients (26.9%) had: a higher disease activity score (DAS28) prior to biologics, at the time of treatment switch and after the observation period; lower drug persistence (p < 0.001 for all tests). Multiple linear regressions showed that ANA positivity is a significant predictor of the current value of DAS28, independently of the presence of RF and/or ACPA (p < 0.05). Conclusion: ANA positivity in RA patients before starting biologics may be a poor prognosis factor for efficacy and drug persistence. Further studies are needed to confirm these observations.
APA, Harvard, Vancouver, ISO, and other styles
28

Pervin, Farhana, Md Anwar Habib, Nazimuddin Ahmed, and Md Mijanur Rahman Sardar. "Effect of combined treatment with Methotrexate and Non-steroidal anti-inflammatory drugs on plasma alpha-tocopherol level and Rheumatoid factor among Rheumatoid Arthritis patients." Mediscope 8, no. 2 (October 4, 2021): 80–86. http://dx.doi.org/10.3329/mediscope.v8i2.55314.

Full text
Abstract:
Background: Oxidative stress might play a significant role in the pathogenesis of Rheumatoid Arthritis. Traditional therapies of Rheumatoid Arthritis are governed by different NSAIDs which improve symptoms of Rheumatoid Arthritis. But addition of Methotrexate (MTX) to Non-steroidal anti-inflammatory drugs (NSAIDs) has been found to be extra beneficial by halting the disease process. Objectives: To evaluate the status of anti-oxidant alpha-tocopherol and rheumatoid factor before and after treatment with MTX and NSAIDs for two months in Rheumatoid Arthritis patients. Methods: This quasi-experimental study was carried out in the Department of Pharmacology and Therapeutics of Rajshahi Medical College, Rajshahi between the periods of January 2011 to December 2011. Total ten clinically diagnosed Rheumatoid Arthritis patients were enrolled in the study. Purposive sampling technique was used to select each study subject from medicine wards of Rajshahi Medical College Hospital. Alpha-tocopherol, an anti-oxidant in plasma was measured as marker of anti-oxidant defense. The patients were then treated with oral MTX at a dose of 10 mg weekly and Indomethacin 150 mg in three divided doses daily for 2 months. After 2 months of continuous aforementioned treatment, alpha-tocopherol levels were estimated again. Moreover qualitative assessment of rheumatoid factor was done. For statistical analysis, paired t-test was done. Results: After two months of treatment with Methotrexate and Indomethacin, plasma alpha-tocopherol levels were significantly higher (P<0.05) in Rheumatoid Arthritis patients. However no significant change was observed in qualitative assessment of rheumatoid factors. Conclusion: From the findings of this study, it can be concluded that the endogenous alpha-tocopherol level increases even without any supplementation of alpha-tocopherol by combined treatment with MTX and Indomethacin in Rheumatoid Arthritis patients and thereby reduces oxidative stress. So alpha-tocopherol level is a better marker for early assessment of prognosis of Rheumatoid arthritis than Rheumatoid factor test. Mediscope 2021;8(2): 80-86
APA, Harvard, Vancouver, ISO, and other styles
29

Mok, Chi Chiu. "EULAR recommendations for the management of rheumatoid arthritis: what is new in 2017 and its applicability in our local setting." Hong Kong Bulletin on Rheumatic Diseases 17, no. 2 (November 22, 2017): 47–52. http://dx.doi.org/10.1515/hkbrd-2017-0009.

Full text
Abstract:
Abstract Rheumatoid arthritis (RA) is the most common rheumatic disease being managed by the rheumatologists. With the emergence of the biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs), the prognosis of RA has improved substantially. However, these novel agents are associated with high cost and untoward effects. International consensus statements for the drug management of RA have been published to guide the practice of rheumatologists. In this article, updates from the 2016 EULAR management recommendations for RA are reviewed and discussed within the context of our local situation in Hong Kong.
APA, Harvard, Vancouver, ISO, and other styles
30

Hashimoto, Teppei, Kohsuke Yoshida, Akira Hashiramoto, and Kiyoshi Matsui. "Cell-Free DNA in Rheumatoid Arthritis." International Journal of Molecular Sciences 22, no. 16 (August 19, 2021): 8941. http://dx.doi.org/10.3390/ijms22168941.

Full text
Abstract:
Endogenous DNA derived from the nuclei or mitochondria is released into the bloodstream following cell damage or death. Extracellular DNA, called cell-free DNA (cfDNA), is associated with various pathological conditions. Recently, multiple aspects of cfDNA have been assessed, including cfDNA levels, integrity, methylation, and mutations. Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, and treatment of RA has highly varied outcomes. cfDNA in patients with RA is elevated in peripheral blood and synovial fluid and is associated with disease activity. Profiling of cfDNA in patients with RA may then be utilized in various aspects of clinical practice, such as the prediction of prognosis and treatment responses; monitoring disease state; and as a diagnostic marker. In this review, we discuss cfDNA in patients with RA, particularly the sources of cfDNA and the correlation of cfDNA with RA pathogenesis. We also highlight the potential of analyzing cfDNA profiles to guide individualized treatment approaches for RA.
APA, Harvard, Vancouver, ISO, and other styles
31

Papadopoulos, Stephen M., Curtis A. Dickman, and Volker K. H. Sonntag. "Atlantoaxial stabilization in rheumatoid arthritis." Journal of Neurosurgery 74, no. 1 (January 1991): 1–7. http://dx.doi.org/10.3171/jns.1991.74.1.0001.

Full text
Abstract:
✓ Atlantoaxial subluxation in patients with rheumatoid arthritis is common. Operative stabilization is clearly indicated when signs and symptoms of spinal cord compression occur. However, many recommend early operative fusion before evidence of appreciable neural compression occurs because 1) the myelopathy in these patients may be irreversible; 2) the overall prognosis is poor once symptoms of cord compression are present; and 3) the risk of sudden death associated with atlantoaxial subluxation is increased even in asymptomatic patients. The authors believe that rheumatoid arthritis patients in relatively good health without advanced multisystem disease and less than 65 years of age should be considered for operative stabilization if mobile atlantoaxial subluxation is greater than 6 mm. Seventeen patients with severe rheumatoid arthritis and atlantoaxial subluxation treated with a posterior arthrodesis are presented. A new method of fusion, devised by the senior author (V.K.H.S.), was utilized in all cases. Indications for operative therapy in these patients included evidence of spinal cord compression in 11 patients (65%) and mobile atlantoaxial subluxation greater than 6 mm but no signs or symptoms of cord compression in six patients (35%). Thirteen patients developed a stable osseous fusion, two patients a well-aligned fibrous union, one patient a malaligned fibrous union, and one patient died prior to evaluation of fusion stability. The details of the operative technique and management strategies are presented. Several technical advantages of this method of fusion make this approach particularly useful in patients with rheumatoid arthritis. Because of multisystem involvement of this disease, a high rate of osseous fusion is often difficult to achieve.
APA, Harvard, Vancouver, ISO, and other styles
32

Alekseeva, Olga, Alexander Smirnov, Alexander Volkov, and Evgeniy Nasonov. "DIAGNOSIS AND PROGNOSIS OF RHEUMATOID ARTHRITIS: FOCUS ON DIAGNOSTIC METHODS." Ultrasound in Medicine & Biology 48 (2022): S40. http://dx.doi.org/10.1016/j.ultrasmedbio.2022.04.118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Kramer, Neil, and Elliot D. Rosenstein. "Assessment and prognosis of rheumatoid arthritis Richard S. Panush, MD." Current Opinion in Rheumatology 4, no. 3 (June 1992): 355–64. http://dx.doi.org/10.1097/00002281-199206000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Lee, Jeong Heon, Sang Youn Jung, G. Kate Park, Kai Bao, Hoon Hyun, Georges El Fakhri, and Hak Soo Choi. "Fluorometric Imaging for Early Diagnosis and Prognosis of Rheumatoid Arthritis." Advanced Science 7, no. 1 (December 2019): 1902267. http://dx.doi.org/10.1002/advs.201902267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Zhdan, V. M., M. V. Tkachenko, M. Yu Babanina, Ye M. Kіtura, and G. V. Volchenko. "ADIPOCYTOKINES IN RHEUMATOID ARTHRITIS: LATENT RELATIONASHIP BETWEEN INFLAMMATION AND CARDIOMETABOLIC COMORBIDITIES." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 21, no. 1 (March 21, 2021): 165–71. http://dx.doi.org/10.31718/2077-1096.21.1.165.

Full text
Abstract:
Rheumatoid arthritis is a chronic autoimmune disease that affects the synovial membrane of the joints and leads to progressive articular damage, disability and reduced quality of life. Despite the emergence of more innovative therapeutic strategies that have improved the duration of remission, rheumatoid arthritis is associated with high levels of comorbidities, infections, malignancies and cardiovascular disease. It is known that some pathogenic proinflammatory mediators in rheumatoid arthritis, such as interleukin-1β (IL-1β) and tumour necrosis factor, may play a central role in the development of cardiovascular disease. Interestingly, various preclinical and clinical studies have shown that biologic agents, who are widely used in the therapy of patients with rheumatoid arthritis, may be effective in the therapy of cardiovascular diseases as well. For this purpose we have studied adipocytokines. Adipocytokines are pleiotropic molecules that are mainly released by white adipose tissue and immune cells. Adipocytokines modulate the function of different tissues and cells, and, in addition to energy homeostasis and metabolism, enhance inflammation, immune response and tissue damage. Adipocytokines may contribute to the proinflammatory conditions in patients with rheumatoid arthritis and the development of bone damage. In addition, they may be associated with the development of cardiovascular disease. In this study, we considered the already known evidence about adipocytokines in the pathogenesis of rheumatoid arthritis, because they are also actively involved in the pathogenesis of cardiovascular disease and are possible biomarkers of prognosis and treatment outcomes, because of their potential, as a possible new therapeutic target.
APA, Harvard, Vancouver, ISO, and other styles
36

Tansathitaya, Vimolmas, Witchana Sarasin, Tanapati Phakham, Vorthon Sawaswong, Prangwalai Chanchaem, and Sunchai Payungporn. "Regulation of mi-RNAs Target Cancer Genes Between Exercise and Non-exercise in Rat Rheumatoid Arthritis Induction: Pilot Study." Epigenetics Insights 15 (January 2022): 251686572211104. http://dx.doi.org/10.1177/25168657221110485.

Full text
Abstract:
Introduction: Rheumatoid arthritis is associated with various cancers. Many studies have investigated physical exercise interventions as health improvements to ameliorate the risk of cancer during rheumatoid arthritis diagnosis. Recently, microRNAs were used as biomarkers for health assessment and cancer prediction in rheumatoid arthritis patients. Methods: The effects of exercise interventions on serum microRNAs were investigated in pristane-induced arthritis (PIA) rat models. Twelve Sprague-Dawley male rats were divided into 4 groups including non-exercise without PIA (N-EX), non-exercise with PIA (N-EX + PIA), exercise without PIA (EX) and exercise with PIA (EX + PIA). Blood samples were collected at the end of the study period to analyze miRNA biomarkers and target cancer gene predictions. Results: Four significant Rattus norvegicus (rno-microRNAs) may purpose as tumor suppressors were identified as potential target cancer gene candidate expressions within the 4 comparative interventional exercise groups. One rno-microRNA and target cancer gene candidate was up-regulated and 3 rno-microRNAs and their target cancer genes were down-regulated. Conclusions: Exercise interventions affected rno-miRNAs regulated target cancer gene candidates ITPR3, SOCS6, ITGA6, and NKX2-1 as biomarkers for cancer prognosis in rheumatoid arthritis diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
37

Utepbergenova, G., G. Kalenderova, and H. Tursynbekova. "Value of Physical Activity in Rehabilitation of Patients With Rheumatoid Arthritis." Bulletin of Science and Practice 6, no. 5 (May 15, 2020): 157–62. http://dx.doi.org/10.33619/2414-2948/54/20.

Full text
Abstract:
A review of the literature on the prognosis of rheumatoid arthritis, physical activity of patients, its role in the development of functional problems that cause restriction of life and decrease in the quality of life, as well as the effectiveness of physical exercise (exercise therapy, physical therapy) in the treatment of this pathology. Particular attention is paid to the good tolerability of exercise therapy, which some authors call additional treatment of patients with rheumatoid arthritis, improving the functional state, but not affecting the course and outcome of the disease.
APA, Harvard, Vancouver, ISO, and other styles
38

de Carvalho Cardoso, Rafaella, Bismarck Rezende, Allan Kardec Nogueira Alencar, Fabrícia Lima Fontes-Dantas, and Guilherme Carneiro Montes. "Role of Arbovirus Infection in Arthritogenic Pain Manifestation—A Systematic Review." Tropical Medicine and Infectious Disease 7, no. 11 (November 21, 2022): 390. http://dx.doi.org/10.3390/tropicalmed7110390.

Full text
Abstract:
The number of publications on the development of arthritic pain after CHIKV infection is increasing; however, there is still a gap in the pathophysiological mechanisms that explain these outcomes. In this review, we conducted a descriptive analysis of the findings of patients to understand their prognosis and to explore therapeutic options. Here, we searched the Cochrane, BVS, PubMed, and Scielo databases using the keywords “arthritis”, “pain”, “arbovirus”, “disease”, “arthritogenic”, and “arthralgia” during the 2000 to 2022 period. Descriptive analyses were conducted to understand the association between CHIKV infection and arthritogenic pain. The present study shows the persistence of acute phase signals for months, making the chronic phase still marked by the presence of arthralgia, often disabling under stimuli, such as temperature variation. CHIKV infection appears to be remarkably similar to rheumatoid arthritis, since both diseases share common symptoms. Once diagnosed, patients are mostly treated with analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease modifying anti-rheumatic drugs (DMARD). As there are no prophylactic measures or specific treatments for arboviruses, this study gathered information on the development and manifestations of arthritogenic pain.
APA, Harvard, Vancouver, ISO, and other styles
39

Vranis, Neil M., Bryan Marascalchi, and Eitan Melamed. "Trends in Proximal Interphalangeal and Metacarpophalangeal Joint Arthroplasty Utilization Using Statewide Databases." Journal of Hand Surgery (Asian-Pacific Volume) 25, no. 01 (January 31, 2020): 39–46. http://dx.doi.org/10.1142/s2424835520500058.

Full text
Abstract:
Background: Arthritis can have profound debilitating effects on the hand secondary to finger deformities and pain. Arthroplasty of the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) can be performed to reduce pain while maintaining joint range of motion. Methods: We used outpatient surgery registries from the states of California and Florida to assess the trends of arthroplasty across several recent years and to determine if the outcomes differ based on disease etiology. Results: We found that there has been a steady decline in number of MCP arthroplasty procedures performed annually between 2005 and 2011 while PIP arthroplasty procedures peaked in 2007 and have since also declined. There was an overall complication rate of 2.4% and no difference in cardiac, respiratory, deep venous thrombosis and infection between patients with osteoarthritis and other arthritic etiologies. However, the risk of device failure in patients with rheumatoid arthritis is found to be significantly higher than for patients with osteoarthritis (p < 0.01). Conclusions: PIP and MCP arthroplasty are safe procedures with an overall low complication rate. The increased risk of device related complications observed in patients with rheumatoid arthritis can be used to appropriately counsel this patient population regarding post-operative expectations and prognosis.
APA, Harvard, Vancouver, ISO, and other styles
40

Khan Khalil, Saifullah, Aamir Kamran, Syed Zahoor Ul Hassan Zaidi, Syed Muhammad Qasim Khan, Rashida Parveen, and Afzaal Akbar. "Frequency of Rheumatoid Arthritis in Young Females Presenting with Multiple Joints Pain Using Acr Diagnostic Criteria." Pakistan Journal of Medical and Health Sciences 16, no. 1 (January 30, 2022): 845–47. http://dx.doi.org/10.53350/pjmhs22161845.

Full text
Abstract:
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease causing morbidity and mortality in all population worldwide. It is present in 1 to 2 % in world's population Objective: To determine the frequency of RA in young females presenting with multiple joints pain using ACR Diagnostic Criteria for RA. Methodology: This study was Descriptive Cross-Sectional Study done at the Department of Medicine, Hayatabad Medical Complex, Peshawar for duration of six months from February 2021 to August 2021. In this study a total of 156 patients were observed to assess the frequency of rheumatoid arthritis in young females with multiple joints pain using ACR Diagnostic Criteria. Results: Serology of RF and ACPA among 156 patients was positive in 93(59.6%) patients and Negative in 63(40.4). Acute phase reactants CRP and ESR among 156 patients were abnormal in 91(58.3%) and Normal in 65(41.7%) patients Conclusion: Our study concludes that in young females with multiple joints pain, the frequency of rheumatoid arthritis was high by using ACR diagnostic criteria. Young females are prone to develop rheumatoid arthritis but remain undiagnosed and this may lead to adverse outcome and failure in prognosis and treatment. If it is diagnosed in early stage it may add to good health outcome and quality of life. Key words: Rheumatoid arthritis; multiple joints pain, ACR Diagnostic Criteria
APA, Harvard, Vancouver, ISO, and other styles
41

M Gema, Bonilla-Hernán, Gómez-Carrera Luis, Fernández-Velilla Peña María, Plasencia-Rodríguez Chamaida, Aguado Pilar, Álvarez-Sala Walther Rodolfo, and Balsa Alejandro. "Mortality and survival of patients with rheumatoid arthritis and symptomatic diffuse interstitial lung disease." Archives of Pulmonology and Respiratory Care 8, no. 1 (October 26, 2022): 003–9. http://dx.doi.org/10.17352/aprc.000075.

Full text
Abstract:
Introduction: In Spain, few data have been reported on mortality and survival in rheumatoid arthritis with diffuse interstitial lung disease. Objectives: To estimate mortality and survival for patients with symptomatic diffuse interstitial lung disease and rheumatoid arthritis and to analyze the effect of clinical factors. Methods: We performed an observational study between 2007 and 2018 at the Interdisciplinary Rheumatology and Pulmonology Clinic, from a tertiary Hospital. Patients with rheumatoid arthritis and symptomatic of diffuse interstitial lung disease confirmed by high-resolution computed tomography were included. Causes of death and clinical factors were reported. Results: We identified 90 patients with rheumatoid arthritis and symptomatic interstitial lung disease. Twenty-six patients died and diffuse interstitial lung disease was the most frequent cause (50%). The overall mortality rate was 19.7 per 1000 patient-years (95% CI: 13.4 - 29). The multivariate model revealed the predictors of mortality to be a long time between diagnosis of rheumatoid arthritis and lung involvement (HR = 1.17; p = 0.003) and low forced vital capacity (HR = 0.02; p = 0.018). The probability of survival was 50% at 10.2 years from diagnosis of interstitial lung disease. Comparison of survival did not reveal significant differences by type of radiologic pattern (p = 0.823). Conclusions: The fact that almost one-third of patients died and that survival is 50% at 10 years highlights the important role of diffuse interstitial lung disease in rheumatoid arthritis. The radiologic pattern does not seem to be as important for survival as forced vital capacity at diagnosis and the time between diagnosis of rheumatoid arthritis and lung involvement. Key points 1. DILD is associated with shorter survival in patients with RA. 2. The radiologic pattern does not seem to influence the survival in patients with RA and DILD. 3. The FVC at diagnosis is an important factor that influences the prognosis of patients with RA and DILD.
APA, Harvard, Vancouver, ISO, and other styles
42

Stevenson, John. "Inflammatory Arthritis." InnovAiT: Education and inspiration for general practice 2, no. 10 (September 22, 2009): 585–96. http://dx.doi.org/10.1093/innovait/inp149.

Full text
Abstract:
Inflammatory arthritis is an umbrella term used to describe a range of conditions, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and reactive arthritis. These are autoimmune diseases in which joint and systemic features are present in varying degrees between disease processes and individuals. Delayed diagnosis can lead to irreversible joint destruction and dysfunction but a therapeutic revolution has transformed its prognosis. Ever-expanding therapeutic options require GPs to recognize these conditions, manage symptoms and undertake drug monitoring. The costs to individuals, their families and the National Health Service are high. There were 1.9 million GP consultations for inflammatory arthritis in 2000 and nearly 46000 hospital admissions. The challenge in primary care is to recognize an inflammatory arthritis early and refer to secondary care.
APA, Harvard, Vancouver, ISO, and other styles
43

Jiaqi, R., J. Zhao, L. Sun, Z. MA, and X. Wang. "FRI0600 DIAGNOSTIC VALUE OF SERUM CONNECTIVE TISSUE GROWTH FACTOR IN RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 906–7. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2080.

Full text
Abstract:
Background:Many autoantibodies are found in the serum of rheumatoid arthritis (RA) patients, including RF, ACPA and so on, which are essential for the disease diagnosis and prognosis judgment. However, 20-30% of patients are still seronegative, so more investigations are needed to find new biomarkers in RA.Objectives:To investigate the prevalence of serum connective tissue growth factor (CTGF) and the association with the clinical features in RA patients.Methods:Serum samples were obtained from 180 patients with RA, 168 patients with other rheumatic diseases, including 43 systemic lupus erythematosus (SLE), 34 osteoarthritis (OA), 17 primary Sjögren’s syndrome (pSS), 20 ankylosing spondylitis (AS), 23 psoriatic arthritis (PsA), 6 reactive arthritis (ReA), 20 systemic sclerosis (SSc), and 5 systemic vasculitis (SV), and 64 healthy individuals in Peking University Third Hospital. The clinical and laboratory data of patients with RA were collected. Levels of CTGF in serum were measured by ELISA. The cut-off value of CTGF was determined by 95 percent of the concentration of the healthy controls. Statistical analyses were performed using the SPSS 24.0 software. Associations between CTGF and the clinical features of RA were evaluated.Results:The prevalence of serum CTGF among RA patients (33.89%) was significantly higher than those of SLE (9.3%), OA (0%), AS (0%), pSS (0%), PsA (0%), ReA (0%), SSc(5%), SV(0%) and healthy controls (4.69%) (p<0.0001). The mean titer of serum CTGF in RA was also significantly higher than those in other rheumatic diseases and healthy controls (p<0.001). At the cutoff value of 264.30 pg/ml, the sensitivity, specificity, positive predictive value and negative predictive value of serum CTGF for RA were 33.89%, 96.55%, 88.41% and 55.45% respectively. Anti-cyclic citrullinated peptide (CCP) antibody (p<0.001), rheumatoid factor (p<0.001), IgG (p=0.025) and IgM (p=0.004) in CTGF-positive patients were higher than those in CTGF-negative patients. Besides, more patients with interstitial lung disease (ILD) were found in CTGF-positive RA.Conclusion:Serum CTGF, as a novel biomarker, has certain diagnostic value for RA. Further studies are necessary to get more knowledge for the diagnostic performance of CTGF in RA.References:[1] Ramazani Y, et al. (2018) Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol 68-69:44-66.[2] Nozawa K, F et al. (2009) Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis research & therapy 11 (6):R174.[3] Yang X, et al. (2017) Serum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis. Arthritis research & therapy 19 (1):257.[4] Wei JL, et al. (2018) Role of ADAMTS-12 in Protecting Against Inflammatory Arthritis in Mice By Interacting With and Inactivating Proinflammatory Connective Tissue Growth Factor. Arthritis & rheumatology (Hoboken, NJ) 70 (11):1745-1756.[5] Tang X, et al. (2018) Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFbeta. Ann Rheum Dis 77 (9):1372-1380.Fig 1.Distribution of serum CTGF in RA, other rheumatic diseases and healthy control. Serum sample were from 180 patients with rheumatoid arthritis (RA), 168 patients with other rheumatic diseases and 64 healthy individuals (HC). Levels of serum CTGF were measured by CTGF ELISA kit. The cut-off value was 263.30 pg/mL (black horizontal dotted line); ***p <0.001Table 1. Demographic, clinical and laboratory features of total RA patients and grouped with serum CTGF.Abbreviations: RA=rheumatoid arthritis; SJC=swollen joint count; TJC=tender joint count; ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; DAS=disease activity score; CCP=cyclic citrullinated peptid; RF=rheumatoid factor. CTGF=connective tissue growth factor; ILD= interstitial lung diseaseDisclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
44

Kunnumpurath, Anthony, Sai Prasad Desikan, Charles McClain, and Raman Desikan. "Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis." Journal of Investigative Medicine High Impact Case Reports 8 (January 2020): 232470962096686. http://dx.doi.org/10.1177/2324709620966863.

Full text
Abstract:
Chronic myelomonocytic leukemia (CMML) is a rare clonal stem cell disorder associated with clinical and pathologic of myelodysplasia and myeloproliferation. Systemic autoimmune/inflammatory disorders (SAID) and polyserositis have been associated with CMML. These manifestations can be observed concomitantly, shortly before diagnosis or anytime along the course of illness. We report a case of myeloproliferative CMML who presented with polyserositis and positive serology for rheumatoid arthritis. Retrospective studies of myelodysplasia/CMML have reported 15% to 25% incidence of SAID. The most commonly observed disorders include systemic vasculitis, connective tissue diseases, polychondritis, seronegative arthritis, and immune thrombocytopenia. SAID does not confer adverse prognosis in retrospective studies. Polyserositis is less common; this may result from leukemic infiltrate or result from autoimmunity. Treatment of serositis includes steroids and cytoreductive agents. Serositis may confer poor prognosis and hypomethylating therapy may improve the outcome.
APA, Harvard, Vancouver, ISO, and other styles
45

Zebadiah Rau, Carissa Ayu, and Gede Kambayana. "Diagnostic Challenges and Management of Patients with Overlapping Rheumatoid Arthritis with Psoriatic Arthritis: A Case Report." International Journal of Research and Review 9, no. 3 (March 16, 2022): 222–27. http://dx.doi.org/10.52403/ijrr.20220326.

Full text
Abstract:
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have key differences in clinical presentation, radiographic findings, and pathogenesis to distinguish between these common forms of chronic inflammatory arthritis. Several case reports report the occurrence of overlapping syndromes of RA with PsA. However, until now, the cases are still very rare. We report A 33-year-old woman, complaining of pain in the joints of her fingers, toes, and her back since eight years ago. The patient also complained of red, silvery-white patches on the abdomen and spread all over the body. On the left hand, there is a swan neck deformity on the fifth finger of the left hand. On the right hand, there is a boutonniere deformity on the second and fourth fingers of the right hand and ulnar deviation of the first finger. On skin examination, it was found with multiple silvery-white erythematous plaques, varying in size, geographical shape, covered with fine white scales spread all over the body skin. The patient was diagnosed with Rheumatoid Arthritis based on the 2010 ACR/EULAR diagnostic criteria, overlapping with Psoriatic Arthritis syndrome based on the 2010 ASAS diagnostic criteria for spondyloarthropathy 2006 CASPAR for PsA. The right diagnosis process speeds up the time for initiation of appropriate therapy to improve quality of life and improve disease prognosis. Keywords: Rheumatoid arthritis, psoriatic arthritis, overlapping syndrome.
APA, Harvard, Vancouver, ISO, and other styles
46

Taylor, Peter, Juliane Gartemann, Jeanie Hsieh, and James Creeden. "A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis." Autoimmune Diseases 2011 (2011): 1–18. http://dx.doi.org/10.4061/2011/815038.

Full text
Abstract:
This systematic review assesses the current status of anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) tests in the diagnosis and prognosis of rheumatoid arthritis (RA). We reviewed publications on tests and biomarkers for early diagnosis of RA from English-language MEDLINE-indexed journals and non-MEDLINE-indexed sources. 85 publications were identified and reviewed, including 68 studies from MEDLINE and 17 non-MEDLINE sources. Anti-CCP2 assays provide improved sensitivity over anti-CCP assays and RF, but anti-CCP2 and RF assays in combination demonstrate a positive predictive value (PPV) nearing 100%, greater than the PPV of either of the tests alone. The combination also appears to be able to distinguish between patients whose disease course is expected to be more severe and both tests are incorporated in the 2010 ACR Rheumatoid Arthritis Classification Criteria. While the clinical value of anti-CCP tests has been established, differences in cut-off values, sensitivities and specificities exist between first-, second- and third-generation tests and harmonization efforts are under way. Anti-CCP and RF are clinically valuable biomarkers for the diagnosis and prognosis of RA patients. The combination of the two biomarkers in conjunction with other clinical measures is an important tool for the diagnosis and management of RA patients.
APA, Harvard, Vancouver, ISO, and other styles
47

Miyaguchi, Fumihiro, Nobuhiko Sunahara, Kousei Ijiri, Teruo Mori, Shunji Matsunaga, and Takashi Sakou. "Prognosis of Unoperated Patients with Cervical Myelopathy due to Rheumatoid Arthritis." Orthopedics & Traumatology 46, no. 1 (1997): 135–37. http://dx.doi.org/10.5035/nishiseisai.46.135.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

KOBAYASHI, TOSHIAKI, SHINSUKE TANAKA, MOTOHARU MAEDA, HIROKO OKUBO, TAKESHI MATSUYAMA, and NOBUO WATANABE. "A study of prognosis in 52 cases with juvenile rheumatoid arthritis." Pediatrics International 35, no. 5 (October 1993): 439–46. http://dx.doi.org/10.1111/j.1442-200x.1993.tb03088.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Matsunaga, Shunji, Takashi Sakou, Toshiyuki Onishi, Kyoji Hayashi, Eiji Taketomi, Nobuhiko Sunahara, and Setsuro Komiya. "Prognosis of Patients With Upper Cervical Lesions Caused by Rheumatoid Arthritis." Spine 28, no. 14 (July 2003): 1581–87. http://dx.doi.org/10.1097/01.brs.0000076912.67557.99.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Chou, CT, HT Liao, CH Chen, WS Chen, HP Wang, and KY Su. "The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases." Biomarker Insights 2 (January 2007): 117727190700200. http://dx.doi.org/10.1177/117727190700200007.

Full text
Abstract:
Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98%) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography